RxDoctor Payments Data

Elliot Jerud, MD

Cardiovascular Disease · Media, PANPI 1578784260

Payments from drug & device makers

$3,096in general payments, 2019–2025

Across 69 payments — averaging $44.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • AstraZeneca$451
  • Amgen$366
  • Boehringer Ingelheim$130
  • Biotronik Inc.$85
  • Johnson & Johnson$72
  • plus $321 from 10 others

What the payments were for

  • Travel & lodging$1,39745%
  • Food & beverage$1,50749%
  • Education$1926%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,096 in reported general payments places this provider in the 60th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$323,472
Medicare patients
965
Services billed
3,972

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban205$260,275
JardianceEmpagliflozin197$243,404
EntrestoSacubitril/Valsartan115$128,091
XareltoRivaroxaban59$68,836
FarxigaDapagliflozin Propanediol51$60,469
Repatha SureclickEvolocumab74$50,733
Rosuvastatin Calcium1,138$18,955
VascepaIcosapent Ethyl14$11,114
Ezetimibe313$10,486
Metoprolol Succinate464$7,689
Omega-3 Acid Ethyl Esters52$3,844
Amlodipine Besylate560$3,681
Losartan Potassium364$3,624
Diltiazem 24hr Er (Cd)Diltiazem Hcl66$3,542
Lisinopril263$1,995

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$260,275205 claims
Boehringer IngelheimJardiance$130$243,404197 claims
NovartisEntresto$24$128,091115 claims
Johnson & JohnsonXarelto$72$68,83659 claims
AstraZenecaFarxiga$451$60,46951 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Media

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →